scholarly journals The Vaccine Coverage and Vaccine Immunity Status and Risk Factors of Non-Protective Levels of Antibodies Against Vaccines in Children with Juvenile Idiopathic Arthritis: Russian Tertiary Centre Study.

2021 ◽  
Author(s):  
Mikhail Kostik ◽  
Natalia A. Lubimova ◽  
Irina V. Fridman ◽  
Olga V. Goleva ◽  
Susanna M. Kharit
Keyword(s):  
Risk Factors ◽  
Hepatitis B ◽  
Vaccine Coverage ◽  
Immunosuppressive Drugs ◽  
Protective Level ◽  
Tertiary Centre ◽  
Methotrexate Treatment ◽  
Systemic Arthritis ◽  
Vaccine Immunity

Abstract Background: Immunosuppressive drugs, decreased vaccine coverage, aberrant immunity might be factors of low anti-vaccine antibodies in JIA patients. The study aimed to evaluate vaccine coverage, post-vaccine immunity and risk factors of non-protective levels of antibodies against measles, mumps, rubella, hepatitis B and diphtheria in JIA patients. Methods: A prospective study included 170 children diagnosed with JIA aged 2 to 17 years, who received routine vaccinations against measles, rubella, mumps (MMR) diphtheria and hepatitis B. In all patients, the levels of post-vaccination antibodies (IgG) for measles, rubella, mumps, hepatitis B and diphtheria measured with ELISA.Results: Protective level of antibodies were 50% against hepatitis B, 52% - diphtheria, 58% - measles, 80% - mumps, 98% rubella. The best coverage for MMR had patients with enthesytis-related arthritis-85%, compare to oligoarthritis-70%, polyarthritis-69%, systemic arthritis-63%. Diphtheria coverage was 50%, 51%, 46%, 63%, respectively. Incomplete MMR vaccination had 39% patients, treated with biologics, 22% with methotrexate and 14% with NSAID (p=0.025), and 61%, 46%, 36% for diphtheria (p=0.021). Incomplete vaccination was a risk factor of non-protective level of antibodies against measles (HR=2.03 [95%CI: 1.02; 4.0], p=0.042), parotitis (HR=6.25 [95%CI: 2.13; 17.9], p=0.0008) and diphtheria (HR=2.39 [95%CI: 1.18; 4.85], p=0.016) vaccines, as well as JIA category, biologics, corticosteroids and long-term methotrexate treatment for distinct vaccines.Conclusion: Children with JIA may have lower anti-vaccine antibodies levels and required routine check, especially in children with incomplete vaccination, biologics, systemic arthritis and long-term methotrexate treatment.

scholarly journals The vaccine coverage and vaccine immunity status and risk factors of non-protective levels of antibodies against vaccines in children with juvenile idiopathic arthritis: cross-sectional Russian tertiary Centre study

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Mikhail M. Kostik ◽  
Natalia A. Lubimova ◽  
Irina V. Fridman ◽  
Olga V. Goleva ◽  
Susanna M. Kharit
Keyword(s):  
Risk Factors ◽  
Hepatitis B ◽  
Vaccine Coverage ◽  
Protective Level ◽  
Serious Adverse Events ◽  
Cross Sectional ◽  
Methotrexate Treatment ◽  
Systemic Arthritis ◽  
Vaccine Immunity

Abstract Background Immunosuppressive drugs, incomplete vaccine coverage, immune system dysregulation might be factors of a low level of anti-vaccine antibodies in JIA patients. The study aimed to evaluate vaccine coverage, post-vaccine immunity, and risk factors of non-protective levels of antibodies against measles, mumps, rubella, hepatitis B, and diphtheria in JIA patients. Methods A cross-sectional study included 170 children diagnosed with JIA aged 2 to 17 years who received routine vaccinations against measles, rubella, mumps (MMR), diphtheria, and hepatitis B national vaccine schedule. In all patients, the levels of post-vaccination antibodies (IgG) for measles, rubella, mumps, hepatitis B, and diphtheria were measured with ELISA. Results Protective level of antibodies were 50% against hepatitis B, 52% - diphtheria, 58% - measles, 80% - mumps, 98% rubella. MMR’s best coverage had patients with enthesitis-related arthritis-85%, compared to oligoarthritis-70%, polyarthritis-69%, systemic arthritis-63%. Diphtheria coverage was 50, 51, 46, 63%, respectively. Incomplete MMR vaccination had 39% patients, treated with biologics, 22% with methotrexate and 14% with NSAID (p = 0.025), and 61, 46, 36% for diphtheria (p = 0.021). Incomplete vaccination was a risk factor of non-protective level of antibodies against measles (HR = 2.03 [95%CI: 1.02; 4.0], p = 0.042), mumps (HR = 6.25 [95%CI: 2.13; 17.9], p = 0.0008) and diphtheria (HR = 2.39 [95%CI: 1.18; 4.85], p = 0.016) vaccines, as well as JIA category, biologics, corticosteroids and long-term methotrexate treatment for distinct vaccines. One-third part of JIA patients continued vaccination against MMR and diphtheria without serious adverse events and JIA flare. There were no differences between patients who continued MMR vaccination or denied in the means of JIA category and treatment options. Patients, continued diphtheria vaccination rare received methotrexate (p = 0.02), biologics (p = 0.004), but had higher levels of anti-diphtheria antibodies (p = 0.024) compare who omitted vaccination. Methotrexate (OR = 9.5 [95%CI: 1.004; 90.3]) and biologics (OR = 4.4 [95%CI: 1.6; 12.1]) were predictors of omitted diphtheria revaccination. Conclusion Children with JIA may have lower anti-vaccine antibody levels and required routine checks, especially in children with incomplete vaccination, biologics, systemic arthritis, and long-term methotrexate treatment. Revaccination of JIA patients was safe and effective.

Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients

2012 ◽  
Vol 27 (2) ◽  
pp. 306-312 ◽  
Author(s):  
Yu Jin Kim ◽  
Hyun Chin Cho ◽  
Dong Hyun Sinn ◽  
Geum-Youn Gwak ◽  
Moon Seok Choi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Renal Impairment ◽  
Chronic Hepatitis B ◽  
Adefovir Dipivoxil

scholarly journals Long term protective level of hepatitis B antibody after revaccination in liver transplanted children: an open-label randomized control trial study

2021 ◽  
Vol 35 (1) ◽  
pp. S141-S141
Author(s):  
Palittiya Sintusek ◽  
Yong Poovorawan ◽  
Supranee Buranapraditkun ◽  
Piyaporn Wanawongsawad ◽  
Ai-lada Intrarakamhang
Keyword(s):  
Hepatitis B ◽  
Randomized Control Trial ◽  
Protective Level ◽  
Open Label ◽  
Randomized Control

scholarly journals Hepatitis B and C among Berlin dental personnel: incidence, risk factors, and effectiveness of barrier prevention measures

2000 ◽  
Vol 125 (2) ◽  
pp. 407-413 ◽  
Author(s):  
A. AMMON ◽  
P. A. REICHART ◽  
G. PAULI ◽  
L. R. PETERSEN
Keyword(s):  
Risk Factors ◽  
Hepatitis B ◽  
Vaccine Coverage ◽  
Hcv Infection ◽  
Prevention Measures ◽  
Society Meeting ◽  
Hbv Vaccine ◽  
Hbv Vaccination ◽  
Prevention Methods ◽  
Dental Assistants

A study of 215 Berlin dentists and 108 dental assistants recruited at the 1997 Berlin Dental Society meeting assessed their occupational risk of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, HBV vaccine coverage, and barrier prevention methods used. Among dentists, 7% (95% CI 4–11) and 0·5% (95% CI 0–3) had serological evidence of previous HBV and HCV infection, respectively. Similar figures for dental assistants were 1% (95% CI 0–5) and 0% (95% CI 0–4). Only 74% of dentists and 63% of dental assistants reported HBV vaccination. Approximately half always used gloves, eye glasses, or face masks. HBV unvaccinated dentists whose patients had HBV risk factors had a greater risk of HBV infection; those who always wore face masks were at lower risk (OR 0·2, 95% CI 0·02–0·98). These data indicate that among Berlin dentists, the HCV risk was lower than that of HBV and that face masks may have lowered the risk of HBV. The use of eye glasses or gloves did not appear to lower the risk of HBV acquisition in this population.

scholarly journals Immunization Coverage of Inmates in Spanish Prisons

2020 ◽  
Vol 17 (21) ◽  
pp. 8045
Author(s):  
Nancy Vicente-Alcalde ◽  
Jose Tuells ◽  
Cecilia M. Egoavil ◽  
Esther Ruescas-Escolano ◽  
Cesare Altavilla ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Hepatitis A ◽  
Vaccine Coverage ◽  
Immunization Coverage ◽  
Vaccine Preventable Diseases ◽  
Inmate Population ◽  
Health Authorities ◽  
Immunodeficiency Virus ◽  
Seasonal Flu

The correct immunization of the inmate population minimizes the risk of transmission of vaccine-preventable diseases in prisons. The objective of this study was to evaluate the vaccine coverage of long-term prisoners in the Spanish penitentiary system through a retrospective longitudinal study. One-thousand and five prisoners were selected, who were imprisoned from 2008 and 2018 in three Spanish prisons. Their degree of immunization was evaluated as related to hepatitis A (HAV), hepatitis B (HBV), tetanus, diphtheria, pneumococcus and seasonal flu. The state of vaccination of the prisoners with a serological diagnosis of HBV, hepatitis C (HCV) and human immunodeficiency virus (HIV) was also evaluated. The vaccination coverage obtained for hepatitis B was 52.3%, and for tetanus–diphtheria, it was 71.9%. However, for hepatitis A and pneumococcus infection, it was insignificant (<2% of the prisoners). Vaccination against seasonal flu was lower than 16%. The HCV and HIV-positive inmates were not correctly vaccinated either. The insufficient level of immunization obtained reflects the lack of interest and marginalization of this population by the penitentiary system and the health authorities. The lack of reliable records is combined with the lack of planned strategies that promote stable and well-defined programs of active vaccination.

scholarly journals Long-Term Prognosis of Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure: A Retrospective Study

2021 ◽  
Author(s):  
Lu Wang ◽  
Wenxiong Xu ◽  
Xuejun Li ◽  
Dabiao Chen ◽  
Yeqiong Zhang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Treatment ◽  
Chronic Liver Failure ◽  
Short Term ◽  
B Virus ◽  
Cirrhotic Patients ◽  
Long Term Prognosis

Abstract Introduction and Objectives: The long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is not well characterized. We sought to assess the short-term and long-term outcomes and the associated risk factors of HBV-ACLF patients in south China.Patients and Methods: We retrospectively analyzed clinical data, adverse events, and clinical endpoint events of HBV-ACLF patients treated at our department between January 2014 and December 2018. Results: A total of 1177 HBV-ACLF patients were included in the study, including 616 (52.3%) cirrhotic patients and 561 (47.7%) non-cirrhotic patients. 973 (83%) patients were associated only with HBV, and 204 (17%) patients had two or more etiologies. The leading cause of simple HBV-ACLF patients was lack of antiviral treatment and the proportion of patients receiving antiviral treatment for HBV was low (20%). Further analyses indicated non-cirrhotic patients had a significantly lower 90-day transplantation‐free mortality and greater 5‐year survival rate than cirrhotic patients (59.5% vs. 27.6%, 62% vs. 36%, P＜0.05). Age, hepatic encephalopathy, liver cirrhosis, nucleoside (acid) analogues (NAs) withdrawal, total bilirubin, and prothrombin time were independent risk factors for 90-day mortality in HBV-ACLF patients. Cirrhosis at admission (AOR=3.675, 95% CI: 2.408–6.594) was a strong independent risk factor for long-term prognosis. Conclusion: The proportion of HBV-ACLF patients receiving antiviral treatment was extremely low in south China. HBV combined with acute hepatitis E, or DILI had no significant effect on the short-term mortality rate in HBV-ACLF patients. Remarkably, the effect of withdrawal of NAs and cirrhosis on short-term outcomes cannot be ignored. No significant improvement in the short-term prognosis of HBV-ACLF patients was observed compared with previous studies. Trial Registration: The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT04231565). Registered 13 May 2020https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S0009OZY&selectaction=Edit&uid=U00036P1&ts=2&cx=27seqt

Sign in / Sign up

Export Citation Format

Share Document